SML0720

Methazolamid

≥98% (HPLC)

• Synonym(e): N-(4-Methyl-2-sulfamoyl-Δ²-1,3,4-thiadiazolin-5-yliden)-acetamid
• Empirische Formel (Hill-System): C₅H₈N₄O₃S₂
• CAS-Nummer: 554-57-4
• Molekulargewicht: 236.27
• EG-Nummer: 209-066-7
• MDL-Nummer: MFCD00083416
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 329825590
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Lagerbedingungen: protect from light
• Farbe: white to beige
• mp (Schmelzpunkt): 208 °C (dec.) (lit.)
• Löslichkeit: DMSO: 20 mg/mL, clear
• Lagertemp.: 2-8°C
• SMILES String: CN1N=C(S\C1=N\C(C)=O)S(N)(=O)=O
• InChI: 1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)/b7-4+
• InChIKey: FLOSMHQXBMRNHR-QPJJXVBHSA-N
• Angaben zum Gen: human ... CA1(759) , CA2(760) , CA4(762) , CA7(766)

Beschreibung

Biochem./physiol. Wirkung

Methazolamide has a plasma half-life of 14 hours in humans. Methazolamide has relatively good lipid solubility and low plasma protein binding ability. Thus, it diffuses into tissues and fluids much more readily than acetazolamide, another carbonic anhydrase inhibitor. Methazolamide has less side effects than acetazolamide.

Methazolamide is a cell-permeable and potent carbonic anhydrase (CA) inhibitor that is used in the treatment of glaucoma. Methazolamide is an insulin sensitizer that reduces hepatic glucose generation in animal models.

Sonstige Hinweise

Light sensitive

Sicherheitshinweise

• Piktogramme: GHS08,GHS07
• Signalwort: Warning
• H-Sätze: H302 + H312 + H332,H351
• P-Sätze: P202 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312 - P308 + P313
• Gefahreneinstufungen: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Carc. 2
• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3